Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen. [PDF]
Int J Antimicrob Agents, 2023 Meropenem in combination with β-lactamase inhibitors (BLIs) and other drugs was tested to identify alternative treatment regimens for multidrug-resistant tuberculosis (MDR-TB).The following were performed: (1) MIC experiments; (2) static time-kill studies (STKs) with different BLIs; and (3) a hollow fibre model system of TB (HFS-TB) studies with ...
Singh S +10 more
europepmc +4 more sources
Infectious Diseases and Therapy, 2020 Plain Language Summary Meropenem-vaborbactam is a new combination antibiotic that was designed specifically for efficacy against bacteria that produce the Klebsiella pneumoniae carbapenemase (KPC) enzyme, which enables resistance to beta-lactam ...
Tanaya Bhowmick, Melvin P Weinstein
exaly +2 more sources
In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Vaborbactam (formerly RPX7009) is a novel inhibitor of serine β-lactamases, including Ambler class A carbapenemases, such as KPCs. The current study evaluated the in vitro activity of the combination agent meropenem-vaborbactam against a global collection of 991 isolates of KPC-positive
Hackel, Meredith A. +4 more
openaire +3 more sources
Infection and Drug Resistance, 2023 Fischer Herald,1 Rodrigo M Burgos1,2 1Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA; 2Department of Medicine, College of Medicine, University of Illinois Chicago, Chicago, IL, USACorrespondence ...
Herald F, Burgos RM
exaly +2 more sources
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Vaborbactam is a member of a new class of β-lactamase inhibitors with inhibitory activity against serine carbapenemases (e.g., Klebsiella pneumoniae carbapenemase) that has been developed in combination with meropenem.
Christopher M, Rubino +5 more
openaire +3 more sources
Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae .
William J. Weiss +8 more
openaire +3 more sources
Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024). [PDF]
J Antimicrob ChemotherSader HS +5 more
europepmc +2 more sources
Successful Treatment with Imipenem/Cilastatin/ Relebactam of a Polymicrobial Bacteremia due to Meropenem/Vaborbactam-Resistant KPC-Kp and Enterococcus Faecalis. [PDF]
Mediterr J Hematol Infect DisMarzi F +5 more
europepmc +2 more sources
Infectious Diseases and Therapy, 2018 Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations.
Richard G. Wunderink +22 more
doaj +2 more sources
Journal of Global Antimicrobial ResistanceObjective: A case of post-neurosurgical ventriculitis caused by a KPC-producing Klebsiella pneumoniae (KPC-Kp) with a ceftazidime/avibactam-resistant, meropenem-susceptible phenotype is reported.
Lorenzo Volpicelli +7 more
doaj +2 more sources